Current Report Filing (8-k)
12 November 2015 - 9:11PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 12, 2015
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
Nevada |
|
000-53605 |
|
26-1265381 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
400
Water Street, Suite 200, Rochester, MI |
|
48307 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: 248-651-6568
(Former name or former address, if changed
since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION
7 – Regulation FD Disclosure
Item 7.01 |
Regulation FD Disclosure |
On November
12, 2015, we issued a press release concerning the appointment of David Smith to the new position of vice president of client
services. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information
in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
SECTION
9 – Financial Statements and Exhibits
Item 9.01 |
Financial Statements and Exhibits |
99.1 |
|
Press release, dated November 12, 2015 |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OptimizeRx
Corporation
/s/
Doug Baker |
|
Doug
Baker
Chief Financial Officer |
|
|
|
Date:
November 12, 2015 |
|
3
Exhibit 99.1
OptimizeRx
Corporation Appoints David Smith
as
Vice President of Client Services
ROCHESTER,
MI – November 12, 2015 – OptimizeRx Corp. (OTCQB: OPRX), a software company whose premier content-delivery platform
enables pharmaceutical companies to provide on-demand patient support services right at point of care, appointed David Smith to
the new position of vice president of client services.
Smith is
an accomplished leader in business development, client services and strategic planning. He has more than 20 years of senior management
experience within leading advertising and marketing companies.
“David
will lead our account reps in developing and expanding our existing account base and advertising agencies,” said David Harrell,
CEO of OptimizeRx. “He will also be responsible for managing and monetizing our relationship with WPP, the world’s
largest marketing services company, to insure we leverage their vast relationships with multiple pharmaceutical clients across
their agencies.”
Prior to
joining OptimizeRx, Smith served as executive vice president of client services at EEI Global, a leading event and marketing company.
Before EEI Global, he served as senior vice president at Campbell-Ewald, a full service marketing communications agency. Earlier,
Smith held a number of senior leadership positions with Toyota and Ford Motor Company in business development, merchandising,
sales and strategic planning.
About
OptimizeRx Corp
OptimizeRx Corporation (OTCQB: OPRX) provides unique consumer and physician
platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical
and healthcare companies effective ways to expand awareness, access and adherence to their medications.
The
company’s core product, SampleMD, replaces drug samples with electronic trial vouchers and copay coupon savings that are
electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading Electronic
Health Record (EHR) platforms in the country, including Allscripts, Quest Diagnostics, Practice Fusion and over 350 other EHRs
to reach over 250,000 healthcare providers. In turn, the company promotes patient savings and support from the world’s largest
pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, please go
to www.optimizerxcorp.com.
Safe
Harbor
This press release contains forward-looking statements within the definition
of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking
statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
Company
Contact:
OptimizeRx
Doug Baker
dbaker@samplemd.com
248-651-6568 x807
Investor
Relations Contact:
Liolios
Group
Ron Both,
Senior Managing Director
oprx@liolios.com
949-574-3860
2
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024